164 related articles for article (PubMed ID: 19713745)
1. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1.
Evdokimova V; Tognon C; Ng T; Sorensen PH
Cell Cycle; 2009 Sep; 8(18):2901-6. PubMed ID: 19713745
[TBL] [Abstract][Full Text] [Related]
2. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
3. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
[TBL] [Abstract][Full Text] [Related]
4. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition.
Evdokimova V; Tognon C; Ng T; Ruzanov P; Melnyk N; Fink D; Sorokin A; Ovchinnikov LP; Davicioni E; Triche TJ; Sorensen PH
Cancer Cell; 2009 May; 15(5):402-15. PubMed ID: 19411069
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
6. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
7. YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.
Kosnopfel C; Sinnberg T; Sauer B; Busch C; Niessner H; Schmitt A; Forchhammer S; Grimmel C; Mertens PR; Hailfinger S; Dunn SE; Garbe C; Schittek B
Mol Cancer Res; 2018 Jul; 16(7):1149-1160. PubMed ID: 29743296
[TBL] [Abstract][Full Text] [Related]
8. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
9. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
Garand C; Guay D; Sereduk C; Chow D; Tsofack SP; Langlois M; Perreault E; Yin HH; Lebel M
Cancer Sci; 2011 Jul; 102(7):1410-7. PubMed ID: 21466612
[TBL] [Abstract][Full Text] [Related]
10. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells.
Punzi S; Balestrieri C; D'Alesio C; Bossi D; Dellino GI; Gatti E; Pruneri G; Criscitiello C; Lovati G; Meliksetyan M; Carugo A; Curigliano G; Natoli G; Pelicci PG; Lanfrancone L
Breast Cancer Res; 2019 Nov; 21(1):123. PubMed ID: 31752957
[TBL] [Abstract][Full Text] [Related]
11. miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.
Sun R; Liu Z; Han L; Yang Y; Wu F; Jiang Q; Zhang H; Ma R; Miao J; He K; Wang X; Zhou D; Huang C
FASEB J; 2019 Apr; 33(4):5411-5424. PubMed ID: 30698996
[TBL] [Abstract][Full Text] [Related]
12. Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells.
Ma JW; Hung CM; Lin YC; Ho CT; Kao JY; Way TD
Oncotarget; 2016 Sep; 7(37):58915-58930. PubMed ID: 27391337
[TBL] [Abstract][Full Text] [Related]
13. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells.
Wang H; Sun R; Chi Z; Li S; Hao L
Mol Cell Biochem; 2017 Sep; 433(1-2):1-12. PubMed ID: 28382490
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells.
Maenz C; Lenfert E; Pantel K; Schumacher U; Deppert W; Wegwitz F
BMC Cancer; 2015 Mar; 15():178. PubMed ID: 25886487
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer.
Fujii T; Yokoyama G; Takahashi H; Namoto R; Nakagawa S; Toh U; Kage M; Shirouzu K; Kuwano M
Breast Cancer; 2008; 15(1):73-8. PubMed ID: 18224398
[TBL] [Abstract][Full Text] [Related]
16. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway.
Chao HM; Huang HX; Chang PH; Tseng KC; Miyajima A; Chern E
Oncotarget; 2017 Jan; 8(2):2604-2616. PubMed ID: 27911878
[TBL] [Abstract][Full Text] [Related]
17. FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression.
Sun R; Xie HY; Qian JX; Huang YN; Yang F; Zhang FL; Shao ZM; Li DQ
Cancer Res; 2018 Sep; 78(18):5274-5286. PubMed ID: 29945959
[TBL] [Abstract][Full Text] [Related]
18. Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro.
Guo TT; Yu YN; Yip GW; Matsumoto K; Bay BH
Anat Rec (Hoboken); 2013 Jun; 296(6):891-8. PubMed ID: 23613305
[TBL] [Abstract][Full Text] [Related]
19. The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion.
Cho KH; Jeong BY; Park CG; Lee HY
Arch Pharm Res; 2019 Jun; 42(6):519-530. PubMed ID: 31004257
[TBL] [Abstract][Full Text] [Related]
20. YB-1 translational control of epithelial-mesenchyme transition.
Mouneimne G; Brugge JS
Cancer Cell; 2009 May; 15(5):357-9. PubMed ID: 19411064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
